Nanomedicine: Nanotechnology, Biology and Medicine
Volume 1, Issue 1 , Pages 47-51 , March 2005

The pathway to commercialization for nanomedicine

  • Ted Flynn, MPA

      Affiliations

    • Potomac Investment Capital, LLC, Sterling, Virginia
  • ,
  • Chiming Wei, MD, PhD

      Affiliations

    • Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland
    • Corresponding Author InformationCorresponding author. 600 N Wolfe St/Blalock 1206, Baltimore, MD 21205.

Received 2 October 2004 ,Accepted 23 November 2004.

References 

  1. Roco M. Report on nanotechnology. Arlington (VA): National Science Foundation; 2003;
  2. Espicom Research. White paper. Chichester (UK): Epsicom Consulting; 2004. Available at: www.espicom.com
  3. Centers for Medicare and Medicaid Services, Health and Human Services. Annual report on prescription expenditures Washington (DC): US Printing office; 2001.
  4. Biotechnology Industry Organization (BIO) 2003 annual report. USA Today, 7 June 2004:1.
  5. Biotechnology Industry Organization annual report. 2003;
  6. Bioworld annual report on life sciences. Bethesda (Md): Ernst and Young; 2003;
  7. National Institutes of Health. Road map for the future of nanomedicine. Bethesda (Md): National Institutes of Health; 2004;
  8. Washington (DC): Food and Drug Administration, Health and Human Services; 2002.
  9. Stormer H. Capital report on nanotechnology. New York: Lux Research; 2002;
  10. Biologic and environmental nanotechnology. 2004;

PII: S1549-9634(05)00013-4

doi: 10.1016/j.nano.2004.11.010

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 1, Issue 1 , Pages 47-51 , March 2005